University of Oxford
The University of Oxford, a collegiate research university, is renowned for its academic excellence and global impact. It comprises a central university with academic departments, research centers, libraries, and museums, alongside 38 self-governing colleges and six permanent private halls. The university's success lies in its unique collegiate system, fostering interdisciplinary collaboration among leading academics and students from diverse backgrounds. Oxford University Innovation, established in 1987, is the university's technology transfer company. It manages the university's intellectual property portfolio, facilitating the commercialization of technologies through licensing, spin-out company formation, and material sales. Additionally, it manages Oxford University Consulting, providing clients access to the university's academic expertise. The university's strategic plan aims to lead the world in research and education, benefiting society on a national and global scale. Oxford University Innovation supports staff and students in applying their expertise and research for wider social and economic impact, sharing income with those involved according to the university's regulations. The university also operates advanced scholarly resources, enabling researchers and students to efficiently discover and engage with relevant academic material.
90 past transactions
Mode Labs
Pre Seed Round in 2025
Mode Labs specializes in developing and manufacturing low-cost, portable, real-time chemical sensors. Utilizing micron-scale quantum technology, their sensors are designed to speciate and quantify pollutants in natural waterways, offering lab-grade sensitivity with plug-and-play functionality. This enables clients to deploy robust, miniaturized, and scalable sensors remotely, providing continuous, real-time data.
Seloxium
Seed Round in 2025
Seloxium is a company focused on transforming the mining, refining, and industrial sectors by providing innovative solutions for wastewater management. Utilizing advanced selective flocculation technology, Seloxium enables the efficient extraction of valuable metals from wastewater and mine tailings. This process not only recovers high-purity metals but also significantly reduces the carbon footprint typically associated with metal extraction. By turning wastewater into a sustainable resource, Seloxium helps its clients meet their environmental and social governance (ESG) goals while simultaneously minimizing the presence of harmful metals in the environment. The company's approach represents a significant advancement in the quest for more sustainable practices within resource-intensive industries.
OrganOx
Venture Round in 2025
OrganOx is a medical device company focused on organ preservation and transplantation, specializing in normothermic preservation technology that mimics physiological conditions to protect livers before transplantation. The company develops and manufactures systems that continuously perfuse livers at body temperature with oxygenated blood, nutrients, and controlled pressures and flows to reduce decay, support bile production, glucose metabolism, and pH stability. Its Metra device stores livers outside the body at normal body temperature, enabling testing and transplantation. OrganOx was founded in 2008 and is based in Oxford, United Kingdom. The technology aims to improve transplant outcomes by maintaining organ viability during storage and enabling more flexible transplantation timelines.
DiffBlue
Series A in 2024
DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.
Fluorok
Seed Round in 2024
FluoRok is a company focused on transforming the production of fluorochemicals through innovative technology. It has developed a patented approach that eliminates the need for dangerous hydrofluoric acid in the manufacturing process. This technology provides a safer, more sustainable, and cost-effective method for producing fluorochemicals, catering to industries such as agrochemicals, pharmaceuticals, and materials. By offering a cleaner alternative, FluoRok aims to enhance access to essential fluorochemicals while promoting environmental sustainability and safety in chemical production.
Oria XR
Pre Seed Round in 2024
Oria XR is an innovative startup dedicated to revolutionizing medical training through the power of Virtual Reality (VR) and extended reality (XR) technologies. Our mission is to empower medical professionals and engineers with cutting-edge technology and unparalleled training experiences, ensuring they have the skills and confidence needed to excel in their fields. At Oria XR, we believe in setting the gold standard in medical training and support.
Oxford Endovascular
Series A in 2024
Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.
Theolytics
Venture Round in 2024
Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.
CryoLogyx
Seed Round in 2024
CryoLogyx is an early-stage biotechnology company that develops cryopreservation technology to produce frozen, ready-to-use cells for drug discovery, diagnostics, and cell therapies. Its approach protects cells during freezing using cryoprotectants, enabling viable cells to be stored and transported in formats tailored to researchers' needs. The technology aims to transform how cells are stored and delivered, ensuring cells and cell therapies are available in the desired format whenever needed.
NodeShift
Seed Round in 2024
NodeShift is a cloud service provider that offers a platform for businesses to create and run secure applications in a cost-effective manner. The company specializes in scalable and decentralized cloud computing services, addressing the challenges associated with decentralization by integrating a comprehensive suite of infrastructure and application services. This unified approach allows businesses to efficiently build and host their applications within a decentralized cloud environment, all through a simplified user interface. By focusing on affordability and security, NodeShift aims to empower companies to leverage the benefits of cloud technology without the complexities typically associated with decentralized systems.
Rhazes AI
Grant in 2023
Rhazes AI is a technology company specializing in an AI-powered platform designed to enhance clinical productivity. Their solution aims to reduce administrative burdens on healthcare professionals by offering an intelligent assistant that can transcribe notes, aid in diagnoses, generate treatment plans, and manage coding and billing tasks. This all-in-one platform also provides specialist-level support, enabling doctors to spend more time with patients and less time on paperwork, thereby reducing physician burnout.
Navenio
Series A in 2023
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.
Theolytics
Series A in 2023
Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.
OxCCU
Series A in 2023
OxCCU develops renewable energy technology to enable a circular economy for fuels, chemicals, and plastics. The technology combines carbon dioxide from the atmosphere with hydrogen from water and renewable electricity to produce fuels, chemicals, and biodegradable plastics and is positioned to deliver the lowest-cost Power to Liquids pathway.
Caristo Diagnostics
Series A in 2023
Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.
OMass Therapeutics
Series B in 2022
OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.
Brainomix
Series B in 2021
Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.
Navenio
Venture Round in 2021
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.
Mach42
Series A in 2021
Machine Discovery is a spin-out from the University of Oxford focused on commercializing advanced machine learning technology. The company has developed a simulation management platform that utilizes proprietary neural network technology to enhance the efficiency of compute-intensive tasks. This platform enables clients to conduct simulations with minimal data input while achieving a high level of accuracy, specifically 99.9% fidelity. By accelerating costly calculations, Machine Discovery provides valuable statistical insights that aid clients in speeding up their innovation processes, thus addressing critical demands in various sectors.
PepGen
Series A in 2020
PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.
Refeyn
Series A in 2020
Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry, a technology that enables the analysis of biomolecules. The company's flagship product, Refeyn One, utilizes single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. Refeyn's innovative optical technology allows researchers to measure the mass of individual molecules across various biologically relevant concentrations without the need for labels, providing both quality-control instruments and advanced research tools. This capability enhances the understanding of biomolecular behavior in their native states, facilitating significant advancements in the field of biochemistry and molecular biology.
Oxford Flow
Venture Round in 2020
Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.
Navenio
Series A in 2020
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.
Perspectum
Venture Round in 2020
Perspectum develops digital health technologies that support clinicians in diagnosing and treating liver disease, diabetes, and cancer. Leveraging precision medicine through advanced imaging and genetics, the company provides AI-driven imaging tools and quantitative health assessments to enable early detection, accurate diagnosis, and targeted therapies. Its software-as-a-service platform delivers disease mapping, quantitative reports, and access to proprietary datasets for AI training, assisting physicians in clinical decision-making and helping pharmaceutical developers advance therapeutic programs. The team includes physicians, biomedical scientists, engineers, and technologists, and Perspectum aims to scale management of complex health problems across healthcare systems.
Oxford VR
Series A in 2020
Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.
Zegami
Series B in 2019
Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.
Zegami
Series B in 2019
Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.
Oxford Semantic Technologies
Series A in 2019
Oxford Semantic Technologies is a company founded in 2017 as a spin-out from the University of Oxford, specializing in the development of RDFox, an advanced knowledge graph and semantic reasoning engine. The company emerged from research initiated in 2011 at the University’s Computer Science Department, aimed at creating a high-performance solution for data-intensive applications. RDFox leverages patented modern computing techniques to provide rapid responses to complex queries, thus enabling enterprise applications for various prestigious partners. The engine is designed to harness the capabilities of modern multi-core architectures, simplifying the querying process for domain experts and reducing reliance on IT specialists. Additionally, RDFox includes features that explain how answers to queries are derived, enhancing clients' ability to validate their results and ensuring confidence in the insights generated.
Oxford VR
Venture Round in 2018
Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.
Evox Therapeutics
Series B in 2018
Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.
Refeyn
Venture Round in 2018
Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry, a technology that enables the analysis of biomolecules. The company's flagship product, Refeyn One, utilizes single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. Refeyn's innovative optical technology allows researchers to measure the mass of individual molecules across various biologically relevant concentrations without the need for labels, providing both quality-control instruments and advanced research tools. This capability enhances the understanding of biomolecular behavior in their native states, facilitating significant advancements in the field of biochemistry and molecular biology.
BibliU
Seed Round in 2018
BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.
Orbit Discovery
Series A in 2018
Orbit Discovery Ltd. is a biotechnology company based in Oxford, United Kingdom, that specializes in peptide display technology for the identification of peptide drugs aimed at treating chronic diseases. Established in 2015, the company utilizes an innovative in vitro display platform that links randomized peptide sequences to their encoding DNA on small beads, facilitating the screening of potential peptide therapeutics. This approach allows for the discovery of peptides that can offer the specificity and efficacy of larger biologic molecules while maintaining the advantages of smaller molecules, such as reduced dosage and lower manufacturing costs. Orbit Discovery's technology enhances the drug development process by enabling high-throughput screening of peptide candidates, thus supporting both internal drug discovery initiatives and collaborative research efforts.
Oxford Flow
Venture Round in 2018
Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.
Brainomix
Venture Round in 2018
Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.
Navenio
Seed Round in 2017
Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.
Oxford Biotrans
Series B in 2017
Oxford Biotrans Limited is a biotechnology company based in Abingdon, United Kingdom, that specializes in the development and commercialization of high-value chemical compounds through enzyme technology. Founded in 2013, the company leverages patented cytochrome P450 enzyme technology to create natural-grade products from readily available feedstocks. Its flagship product, Nootkatone, is a grapefruit-flavored and scented compound derived from the biotransformation of Valencene, a citrus extract. Oxford Biotrans is focused on producing flavors and fragrances, while its technology also holds potential for applications in pheromones, pharmaceuticals, and other specialty chemicals. The company's innovations are grounded in over 15 years of research from the Department of Chemistry at the University of Oxford, emphasizing environmentally friendly practices that reduce chemical waste and energy consumption in production processes.
Zegami
Series A in 2017
Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.
DiffBlue
Series A in 2017
DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.
Scenic Biotech
Series A in 2017
Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.
Bodle Technologies
Seed Round in 2017
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.
Fuel3D
Venture Round in 2017
Fuel3D produces an affordable handheld 3D scanner that captures high‑resolution shape and color data in seconds. The device combines pre‑calibrated stereo cameras with photometric imaging, enabling rapid, accurate 3D modeling for applications such as gaming, animation, and product design. Developed by a team of engineers and scientists at Oxford University, the technology originated in medical imaging and has been adapted for broader creative and industrial use. Fuel3D offers a point‑and‑shoot system that is significantly cheaper than traditional scanners, making high‑quality 3D capture accessible to independent developers, designers, and artists. The company is led by CEO Stuart Mead, who brings experience from multiple successful technology ventures.
Fungry
Venture Round in 2017
Fungry is an online food application focused on enhancing the takeaway dining experience in Oxford by connecting customers with independent restaurants. The company emphasizes the importance of supporting local establishments while ensuring that users can enjoy high-quality, diverse cuisine without the hassle of searching for options. By partnering with various local chefs, Fungry curates a selection of exceptional dishes, allowing customers to conveniently order food that reflects the unique culinary landscape of the area. This approach not only promotes local dining but also caters to a range of tastes and preferences, making it easier for residents to enjoy excellent meals from the comfort of their homes.
Covatic
Series A in 2017
Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.
Cycle.land
Equity Crowdfunding in 2016
Cycle.land Limited is an online bicycle sharing platform based in Oxford, United Kingdom, with additional offices in Cambridge and Edinburgh. Founded in 2016, the company connects bike owners with individuals in need of a bicycle, facilitating rentals during times when the owners are not using their bikes. The platform caters to a diverse audience, including college students, residents, and tourists, promoting a community of cycling enthusiasts who value sharing and collaboration. By allowing users to easily find, share, and book bicycles from local owners, Cycle.land aims to create a vibrant social marketplace that encourages sustainable transportation and fosters connections among users. The company has garnered support from the University of Oxford, recognizing its potential to enhance community engagement and promote cycling as an enjoyable and eco-friendly mode of transport.
Redacto
Venture Round in 2016
Redacto represents a totally new approach to online language learning. Using authentic recordings of people from different walks of life, as well as news broadcasts and vox pops, Redacto provides English language learners of all levels with intensive and relevant listening practice. Users are supported by hints, score feedback, variable audio speed and Google’s speech to text technology. Students can invite a friend to compete against online. Both users can collaborate in real time as they see each other’s correctly guessed words populate their screens, along with scores and feedback. Learning is consolidated by post listening vocabulary exercises.
Cycle.land
Venture Round in 2016
Cycle.land Limited is an online bicycle sharing platform based in Oxford, United Kingdom, with additional offices in Cambridge and Edinburgh. Founded in 2016, the company connects bike owners with individuals in need of a bicycle, facilitating rentals during times when the owners are not using their bikes. The platform caters to a diverse audience, including college students, residents, and tourists, promoting a community of cycling enthusiasts who value sharing and collaboration. By allowing users to easily find, share, and book bicycles from local owners, Cycle.land aims to create a vibrant social marketplace that encourages sustainable transportation and fosters connections among users. The company has garnered support from the University of Oxford, recognizing its potential to enhance community engagement and promote cycling as an enjoyable and eco-friendly mode of transport.
Bodle Technologies
Seed Round in 2015
Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.
Xerion Healthcare
Series A in 2015
Xerion Healthcare Limited is a biotechnology company based in Thame, United Kingdom, specializing in the development and commercialization of nanoparticle treatments for cancer. Founded in 2015, the company focuses on enhancing the efficacy of conventional radiotherapy by utilizing nanoparticles made from titanium dioxide, a non-toxic semiconductor material. These nanoparticles are injected into tumors prior to standard radiotherapy, where they amplify the generation of free radicals produced by X-rays, thereby improving treatment outcomes. Xerion Healthcare is particularly concentrated on developing its innovative technology for head, neck, and pancreatic cancers, aiming to provide more effective therapies while minimizing side effects for patients.
Gyana
Seed Round in 2015
Gyana is a software company that specializes in creating user-friendly tools for data analysis and visualization. Their primary product is a next-generation report and dashboard tool designed to simplify the process of deriving valuable insights from data. Gyana's platform uses no-code interfaces, allowing users without programming knowledge to access advanced data science capabilities. It automatically connects with various digital tools to collect data, interprets it instantly, and refreshes it automatically. Users can manipulate data, perform calculations, and create visualizations using preset models. The platform also offers templates for specific use cases, enabling users to generate comprehensive reports quickly. Gyana facilitates easy sharing of reports and dashboards in PDF format and plans to introduce automated report delivery via email and live public links for dashboards in the future.
Wrapidity
Convertible Note in 2015
Wrapidity Limited, founded in 2015 and based in London, specializes in web data extraction, transforming unstructured and semi-structured web content into structured data formats. As a subsidiary of Meltwater News US Inc., the company offers an artificial intelligence-driven platform that automates the process of data extraction from various websites. This innovative approach eliminates the need for expensive engineering resources typically required for building and maintaining web scrapers. Clients simply provide a small sample of the desired data, and Wrapidity's AI determines how to navigate the web, fill out forms, and extract relevant information efficiently. The resulting structured data can enhance search capabilities, recommendations, and analytics for businesses, policymakers, and researchers, thereby streamlining data collection and usage while reducing costs.
Total Mama
Venture Round in 2014
Total Mama is a digital health company focused on supporting women throughout their pregnancy journey, from pre-conception to postpartum. The company provides personalized and evidence-based health information related to pregnancy and fertility, utilizing AI-based technology to tailor guidance according to individual health profiles and demographic data. By aligning this information with national clinical guidelines and other reputable sources, Total Mama ensures that women have access to reliable maternal and reproductive health resources. This innovative approach aims to empower women with the knowledge and support they need during this critical phase of their lives.
Genomics
Series A in 2014
Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.
Oxa
Seed Round in 2014
Oxa is a developer of autonomous vehicle software that focuses on creating AI-based platforms for the operation and scaling of fleets of autonomous vehicles. The company's technology combines laser vision and radar for effective localization, allowing autonomous systems to understand their surroundings and navigate safely in complex environments. Oxa's software is designed to operate with low compute power requirements, making it accessible for various business applications. By providing solutions that enhance vehicle positioning and movement prediction, Oxa enables clients to implement and accelerate the deployment of autonomous vehicles in a range of settings.
Oxford BioChronometrics
Venture Round in 2014
Oxford BioChronometrics, founded in 2014, specializes in developing cybersecurity software solutions to combat digital fraud in online advertising and e-commerce transactions. The company offers two primary product suites: Digital Media Solutions and Cyber Solutions. Digital Media Solutions quantifies fraud by identifying non-human traffic (bots) and provides actionable data for advertisers to improve return on investment and ensure brand safety. Cyber Solutions prevent fraud by ensuring human-only access through continuous credential validation, offering products such as Secure Form, SecureLeads, and Secure Checkout. The company has gained recognition for its innovative technology, winning the NATO 2017 Defense Innovation Challenge and leading the field in industry testing.
Adaptimmune Therapeutics
Series A in 2014
Adaptimmune Therapeutics is a biopharmaceutical company focused on developing novel cell therapies to treat solid tumors. It employs its proprietary SPEAR T-cell platform to identify cancer targets and generate therapeutic candidates for clinical trials.
Oxitec
Venture Round in 2014
Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative and environmentally friendly solutions for controlling insect pests that threaten global health and agriculture. Founded in 2002, the company utilizes proprietary technology derived from research at the University of Oxford, which incorporates genetics and molecular biology to enhance the effectiveness and safety of the Sterile Insect Technique (SIT). Oxitec offers a range of products, including genetically modified strains of Aedes aegypti and Aedes albopictus mosquitoes, as well as various agricultural pests such as the diamondback moth and pink bollworm. These products are designed to reduce pest populations in a targeted and sustainable manner, minimizing the impact on ecosystems and human health. Oxitec also operates a mosquito production facility in Piracicaba, Brazil, furthering its mission to combat diseases like dengue fever and protect crop yields.
OxSyBio
Seed Round in 2014
OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.
Designer Carbon Materials
Seed Round in 2014
Designer Carbon Materials Ltd is a company focused on the development of advanced nanomaterials, specifically endohedral metallofullerenes, for diverse applications in energy harvesting, bio-sensing, and quantum nanoelectronics. Founded as a spin-out from the University of Oxford, it builds upon over a decade of research led by Dr. Kyriakos Porfyrakis and his team. The company specializes in synthesizing and chemically functionalizing these unique carbon structures to tailor their electronic properties for various industrial and scientific uses. By licensing a comprehensive intellectual property portfolio developed by Dr. Porfyrakis and his group, Designer Carbon Materials Ltd aims to provide innovative solutions that leverage the capabilities of carbon nanostructures.
Singular Intelligence
Venture Round in 2014
Singular Intelligence Limited is a London-based company that develops an advanced artificial intelligence platform tailored for business and insight teams in sectors such as consumer packaged goods, food and drink, beauty, and home care products. Established in 2013, the company specializes in automating and enhancing commercial decision-making processes with high accuracy by leveraging market data. Its offerings include solutions for price and promotion decisions, marketing mix modeling, supply planning forecasting, and marketing investment strategies. Singular Intelligence also provides tools for retail, e-commerce, and direct-to-consumer automation. The company's flagship product, SiDAX™, utilizes big data and visual analytics to deliver dynamic insights that facilitate timely and informed decision-making. As an Oxford University startup, Singular Intelligence focuses on the intersection of consumer behavior, retail dynamics, and smart technologies, positioning itself as a leader in analytics and big data solutions.
Genomics
Seed Round in 2014
Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.
OxCEPT
Seed Round in 2014
OxCEPT is a developer of advanced cybersecurity solutions, specializing in a military-grade authentication application that ensures secure real-time communication. The company has created a cross-platform, front-end mobile application paired with a robust back-end server system that enhances data transmission security. Its proprietary technology, protected by patents and intellectual property, allows for the secure transfer of information across various devices. By providing authentication and encryption products, OxCEPT enables organizations, including those in the military sector, to establish secure communication channels, safeguarding sensitive data and communications from unauthorized access.
Chronos Therapeutics
Venture Round in 2013
Chronos Therapeutics is a drug development company dedicated to creating therapies for age-related diseases, with a particular emphasis on nervous system disorders. The company engages in comprehensive research and development activities, which include repositioning existing drugs and discovering novel proprietary drug candidates. By focusing on innovative treatment options, Chronos Therapeutics aims to provide healthcare professionals with advanced solutions that enhance patient recovery and address the complexities of age-related conditions.
Oxford MEStar
Seed Round in 2013
Oxford MEStar develops and offers bioengineering products and services for translational and regenerative medicine. The company provides technologies and solutions to scale up human cell and stem cell processing, manufacture engineered tissues and cellular bioproducts, and apply bioprocessing and biomanufacturing expertise. It enables clients to access three-dimensional bioprinting, in vitro diagnostic development, and related bioengineering alternatives to advance tissue engineering and stem cell therapies.
VDabble
Venture Round in 2013
VDabble is a company that specializes in delivering educational and entertaining activities for children aged 3 to 7 years through a subscription-based service. Their primary product, the DabbleBox, is a themed monthly package filled with various tools, learning puzzles, pictorial charts, and craft books. Each box is designed to inspire creativity and facilitate learning in a fun and engaging manner. By providing all necessary supplies directly to customers' doors, VDabble enables young children to explore new lessons and enhance their creativity through play and interactive experiences.
Perspectum
Seed Round in 2013
Perspectum develops digital health technologies that support clinicians in diagnosing and treating liver disease, diabetes, and cancer. Leveraging precision medicine through advanced imaging and genetics, the company provides AI-driven imaging tools and quantitative health assessments to enable early detection, accurate diagnosis, and targeted therapies. Its software-as-a-service platform delivers disease mapping, quantitative reports, and access to proprietary datasets for AI training, assisting physicians in clinical decision-making and helping pharmaceutical developers advance therapeutic programs. The team includes physicians, biomedical scientists, engineers, and technologists, and Perspectum aims to scale management of complex health problems across healthcare systems.
Starticles
Venture Round in 2013
Starticles is an online platform that enables individuals to showcase their knowledge and creativity, allowing them to gain recognition based on the content they create rather than their formal qualifications. Users can share their ideas, research, and insights with the Starticles community, which provides ratings and feedback on the submitted content. This engagement helps users earn recognition and points, ultimately enhancing their professional profiles and career opportunities. By focusing on user-generated content and community feedback, Starticles fosters an environment where expertise is valued, thereby empowering individuals to demonstrate their capabilities in a meaningful way.
Oxpert
Venture Round in 2013
Oxpert is a developer of online business software specifically designed for micro businesses, with a focus on tradespeople including gas engineers and electricians. The company's tools enable these small enterprises to enhance their online presence and efficiently manage various operational aspects of their businesses. By providing essential brand and operations management resources, Oxpert empowers tradespeople to grow their businesses and compete effectively against larger competitors in the market.
OxLegal
Venture Round in 2013
OxLegal is a software venture designed to address the challenges faced by legal professionals. The company develops tools that enhance workflow processes for law firms, including features such as semantic tagging and natural language aids for contract drafting and due diligence. These productivity-related tools enable lawyers to complete tasks more efficiently, significantly reducing time and costs associated with IT implementation and staff training. By streamlining these processes, OxLegal allows legal practitioners to focus on higher-value strategic work while also mitigating risks and protecting their reputations.
TipTapped
Venture Round in 2013
TipTapped is a sports data provider. We analyse social media to find out what people are saying about upcoming sports games. TipTapped aggregate the data to show outcome forecasts for upcoming games, along with the complete prediction histories for each individual.We then share this data with sports fans, sports media and other sports companies.
Edspire
Venture Round in 2013
Edspire is a pioneering business that operates as a comprehensive search engine for online learning resources. It employs advanced algorithms to categorize and curate a vast array of educational content, including Massive Open Online Courses (MOOCs), videos, OpenCourseWare, tutorials, and screencasts. The company's core offering is a robust set of tools designed to assist users in planning their personalized learning journeys. Edspire was incubated by Isis Innovation, the technology transfer company of the University of Oxford.
Oxford Vacmedix
Seed Round in 2013
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang - Recombinant Overlapping Peptides (ROP).
These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical.
Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
goKomplain
Venture Round in 2012
goKomplain lets you to voice your discontent and allows the public to offer solutions.
SmartEatOut
Venture Round in 2012
SmartEatOut is a group dining solution bringing together people and restaurants. By signing up for free people can join Smart-groups and meet others around the table or simply book a table for a private celebration with their friends.
Oxehealth
Seed Round in 2012
Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, that specializes in non-contact vital signs monitoring. Founded in 2012, it has developed the Oxecam software, which allows for the remote measurement of heart rate, respiratory rate, and blood oxygenation using digital video cameras. This innovative approach is particularly beneficial in medical settings, where it can enhance care for elderly and vulnerable individuals in environments where staff presence is limited. The system generates alerts for risky activities and provides objective data on patient vitals, enabling informed care planning. Oxehealth's technology combines proprietary algorithms that leverage deep learning, computer vision, and signal processing, making it suitable for various sectors, including healthcare, security, and retail. Its Digital Care Assistant supports clinicians and caregivers in mental health facilities, prisons, and home care, facilitating proactive interventions based on real-time data. Oxehealth is recognized for achieving the world’s first medical device certification for its software, demonstrating its commitment to enhancing patient care through innovative technology.
Brainomix
Venture Round in 2012
Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.
Onfido
Convertible Note in 2012
Onfido Limited, established in 2010 and headquartered in London, specializes in digital identity verification. The company offers a SaaS solution that uses AI-based technology to verify government-issued IDs and match them with facial biometrics, ensuring users' identities are genuine. Onfido's platform is employed in various sectors, including financial services, marketplaces, gaming, and e-commerce, for applications such as KYC, user onboarding, and fraud detection. The company operates globally with offices in major cities like San Francisco, New York, Lisbon, Paris, New Delhi, and Singapore.
MeVitae
Venture Round in 2012
MeVitae develops a talent intelligence platform that promotes fair hiring practices. It uses anonymized CV screening and ethical AI-driven decision-making, integrating seamlessly with HR systems to enable inclusive hiring for enterprise and public sector organizations.
WhatsOnCampus
Venture Round in 2012
WhatsOnCampus connects students to activities happening on and around their campus.
Active Inspiration Technologies
Venture Round in 2012
Award winning digital health platform called "Fuell" with a goal of getting Employees to achieve weekly health goals.
Data Collection from wearables
Engagement through self service and sponsored challenges
Loyalty and Monetisation through tokens
Low cost monthly subscription with data driven outcomes for Employers, Brands and Organisations.
Oxford Imaging Detectors
Seed Round in 2011
Oxford Imaging Detectors develops high performance scientific imaging detectors capable of studying structures and processes at the atomic level.
Esplorio
Venture Round in 2011
Esplorio is a digital travel journal platform and mobile application based in Oxford, United Kingdom. Founded in 2012, the company operates an online platform that enables users to add updates about their travels and to compile social media content and travel data into a personal travel diary. Through its iOS app, Esplorio helps users record the places they have visited, relive their adventures, and share experiences with others, effectively serving as a travel guide and social travel journal. The product transforms scattered travel information into a coherent record of journeys, providing a platform for users to curate and showcase their travels.
OxGeos
Venture Round in 2011
Oxford Geo-Social Technologies – OXGEOS™ was founded in March 2012, in Oxford, United Kingdom. OXGEOS has a core team of Oxford Graduates who are motivated by a world of possibilities for geo-social technology.OXGEOS provides world class platforms for social games, social communities and geo-social advertising technologies.
Pilio
Venture Round in 2011
Founded in London in 2011, Pilio specializes in energy management software. It employs advanced algorithms for weather analysis and energy efficiency benchmarking to accurately track savings. The company offers intuitive dashboards and reports, empowering businesses to make lasting financial, energy, and carbon savings across their estates.
Colwiz
Venture Round in 2011
colwiz (collective wizdom) is a free research management, collaboration and productivity platform for individual researchers, groups, departments and organizations.
Utilizing web, desktop (Windows, Mac , Linux) and mobile applications synced in real time, the platform manages the entire research lifecycle from an initial idea, through a complex collaboration, to publication of the results.
colwiz
The company was founded by leading researchers from the University of Oxford.
IXO Therapeutics
Seed Round in 2010
IXO Therapeutics Ltd. is a biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases.
Kepler Energy
Seed Round in 2010
Kepler Energy Limited is a development-stage company based in the United Kingdom, founded in 2010. The company specializes in the design, development, and manufacture of advanced tidal turbines, which are intended to harness tidal energy efficiently. Kepler holds an exclusive license for a patented second-generation tidal turbine initially developed by academics from the University of Oxford. The design focuses on optimizing performance for tidal streams with lower velocities, making it suitable for widespread application in coastal waters. The turbines can be deployed both individually and in arrays, known as tidal fences, which allow for incremental revenue generation during the construction phase. Kepler's technology aims to disrupt the existing market by providing a more scalable and powerful solution, particularly in areas where first-generation turbines are not economically viable, thereby facilitating access to a sustainable and predictable energy source.
Navetas Energy Management
Series B in 2010
Navetas Energy Management Ltd. is an energy management company based in Woodbridge, United Kingdom, founded in 2008. It specializes in providing cloud-based energy monitoring and smart data analytics solutions primarily for residential customers. The company's primary offering is the Loop connected energy platform, which enables users to monitor their electricity and gas consumption through real-time analytics accessible on various devices. The platform includes the Loop Electricity Starter Kit, which features a sensor and Internet gateway, and the Loop Gas meter for monitoring gas usage. Additionally, Navetas provides a subscription service that allows customers to receive automated tariff advice, helping them compare and manage their energy costs effectively. The company also offers a range of services in energy measurement, procurement, and conservation across industrial and commercial sectors, including the Navetas Zeo Smart Hub for comprehensive meter management. Navetas Energy Management Ltd. previously operated under the name Navetas New Co., Ltd. before rebranding in September 2008 and is currently undergoing reorganization.
Oxford Immunotec
Series D in 2010
Oxford Immunotec is a diagnostics company specializing in the development and commercialization of proprietary tests for immunology and infectious diseases. Headquartered in the UK, with operations in the US, the company's core technology, T-SPOT, measures specific T cell responses to inform diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Its flagship product, T-SPOT.TB, detects active and latent tuberculosis infection, while T-SPOT.CMV monitors cytomegalovirus in transplant recipients. Oxford Immunotec serves independent laboratories, hospital systems, and public and private institutions worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.